Over the last few years, MitoKor Inc. has constructed a platform of technologies geared towards developing drug candidates based on an understanding of the mitochondria. But with preclinical candidates not expected to enter the clinic any time soon, the company last week said it would acquire Apollo BioPharmaceutics Inc., adding a clinical pipeline where once there was none.

Walter Moos, chairman and CEO, said the deal adds a third leg to MitoKor's areas of focus: mitochondrial research; combichem and medicinal chemistry technologies to design small molecule compounds, and clinical stage therapeutics